Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope, or peripheral edema
How does the Smoothbeam compare to blue-light devices
Our cross-sectional design limits our ability to determine whether these observed changes represent primary pathophysiology originating in childhood ASD or compensatory mechanisms developing during adulthood
Retatrutide, by activating GLP-1, GIP, and glucagon receptors, may provide faster and more significant weight loss, along with enhanced fat metabolism, giving it a broader metabolic effect compared to semaglutide
Downstream effects (IGF-1 elevation, body composition changes, recovery markers) take 24 weeks to manifest because IGF-1 synthesis lags behind GH pulses
A 2018 rat study showed that it increased GH receptor expression in tendon cells and activated key growth pathways, making tissues more responsive to circulating GH